Development of heart failure is independent of K+ channel-interacting protein 2 expression

Tobias Speerschneider1, Søren Grubb, Artina Metoska

  • 1M. B. Thomsen: Danish National Research Foundation Centre for Cardiac Arrhythmia, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, 3b Blegdamsvej, building 12.5.36, Copenhagen N, Denmark. mbthom@sund.ku.dk.

Insights

Reduced KChIP2 expression in heart failure (HF) does not cause HF but lowers arrhythmia susceptibility. Downregulation of KChIP2 in HF may be antiarrhythmic by reducing the transient outward K(+) current.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Electrophysiology

Background:

  • Abnormal ventricular repolarization is a key factor in arrhythmias and sudden cardiac death.
  • K(+) channel-interacting protein 2 (KChIP2) expression decreases in heart failure (HF), reducing the transient outward K(+) current (Ito).

Purpose of the Study:

  • To investigate the role of KChIP2 expression changes in HF development and proarrhythmia.
  • To determine if KChIP2 downregulation contributes to HF or affects arrhythmia susceptibility.

Main Methods:

  • Created heart failure in wild-type (WT) and KChIP2(-/-) mice using transverse aortic constriction (TAC).
  • Monitored cardiac function via echocardiography and recorded ECGs.
  • Induced arrhythmias through in vivo heart pacing and analyzed ventricular tissue.

Main Results:

  • HF development was similar in WT and KChIP2(-/-) mice post-TAC.
  • KChIP2 expression decreased significantly in WT mice with HF.
  • KChIP2(-/-) mice, with or without HF, showed reduced susceptibility to pacing-induced ventricular tachycardia (VT).

Conclusions:

  • KChIP2 downregulation is not the driver of HF development.
  • KChIP2 influences ventricular repolarization and decreases arrhythmia risk.
  • Reduced KChIP2 in HF might be an antiarrhythmic mechanism by decreasing Ito.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
2.3K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
5.1K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
2.0K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
2.1K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
2.1K
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
1.4K